Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months ...
Sierra Nevada Corp.’s Dayton footprint has expanded rapidly since 2023, but a company leader say the biggest challenge isn’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results